Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study

Fig. 1

Study design schematic. Flow chart illustrating the study design. A total of 21,747 treatment-naïve patients diagnosed with lung cancer were retrospectively screened for ROS1 fusion variants. Among them, 447 were detected with ROS1 rearrangements using various methods including NGS (n = 264), FISH (n = 105), and ARMS (n = 78). Clinical outcomes were further analyzed for the 235 patients with ROS1-rearranged locally advanced to advanced lung cancer who received either chemotherapy (n = 67) or crizotinib (n = 168) as first-line therapy

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us